Establishment Labs Holdings Inc. (NASDAQ:ESTA) Given Average Rating of “Moderate Buy” by Brokerages

Establishment Labs Holdings Inc. (NASDAQ:ESTA) has earned a consensus recommendation of “Moderate Buy” from the eight analysts that are covering the firm, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and six have assigned a buy recommendation to the company. The average 12 month target price among analysts that have updated their coverage on the stock in the last year is $86.8571.

A number of brokerages recently issued reports on ESTA. Canaccord Genuity Group lifted their price target on shares of Establishment Labs from $85.00 to $90.00 and gave the stock a “buy” rating in a research note on Thursday, February 26th. JPMorgan Chase & Co. lifted their price target on Establishment Labs from $71.00 to $80.00 and gave the stock an “overweight” rating in a report on Wednesday, December 17th. Needham & Company LLC raised their target price on Establishment Labs from $84.00 to $86.00 and gave the stock a “buy” rating in a research report on Tuesday, February 24th. Mizuho increased their price target on shares of Establishment Labs from $90.00 to $100.00 and gave the company an “outperform” rating in a research note on Wednesday, February 25th. Finally, Stephens boosted their price objective on shares of Establishment Labs from $85.00 to $90.00 and gave the stock an “overweight” rating in a research report on Wednesday, February 25th.

Establishment Labs Stock Performance

ESTA opened at $55.31 on Monday. Establishment Labs has a 12 month low of $26.56 and a 12 month high of $83.31. The stock has a market capitalization of $1.62 billion, a price-to-earnings ratio of -31.79 and a beta of 0.91. The company has a debt-to-equity ratio of 10.51, a current ratio of 3.04 and a quick ratio of 2.00. The business has a fifty day moving average price of $68.98 and a 200 day moving average price of $62.21.

Establishment Labs (NASDAQ:ESTA) last posted its quarterly earnings results on Tuesday, February 24th. The company reported ($0.09) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.22) by $0.13. The company had revenue of $64.62 million for the quarter, compared to analyst estimates of $63.80 million. Establishment Labs had a negative return on equity of 201.79% and a negative net margin of 24.19%.Establishment Labs’s revenue for the quarter was up 45.2% compared to the same quarter last year. During the same quarter last year, the company earned ($1.19) EPS. Sell-side analysts expect that Establishment Labs will post -2.41 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Establishment Labs news, Director Quiros Juan Jose Chacon sold 3,575 shares of the company’s stock in a transaction on Wednesday, March 25th. The shares were sold at an average price of $60.08, for a total value of $214,786.00. Following the completion of the transaction, the director owned 1,220,004 shares in the company, valued at $73,297,840.32. This represents a 0.29% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. 11.44% of the stock is currently owned by company insiders.

Institutional Trading of Establishment Labs

Hedge funds and other institutional investors have recently made changes to their positions in the company. MV Capital Management Inc. purchased a new stake in shares of Establishment Labs in the 4th quarter valued at about $146,000. ADAR1 Capital Management LLC grew its stake in Establishment Labs by 89.0% during the 4th quarter. ADAR1 Capital Management LLC now owns 171,422 shares of the company’s stock worth $12,493,000 after buying an additional 80,734 shares during the last quarter. Voloridge Investment Management LLC acquired a new position in Establishment Labs during the fourth quarter worth approximately $3,421,000. SummitTX Capital L.P. purchased a new stake in Establishment Labs in the fourth quarter valued at approximately $2,519,000. Finally, Tudor Investment Corp ET AL purchased a new stake in Establishment Labs in the fourth quarter valued at approximately $12,852,000. Institutional investors and hedge funds own 72.91% of the company’s stock.

Establishment Labs Company Profile

Establishment Labs Holdings Inc is a global medical technology company specializing in the design, development and manufacture of silicone gel breast implants for aesthetic and reconstructive surgery. The company’s proprietary portfolio is built around patient-focused safety, customization and innovation, offering solutions intended to enhance surgical outcomes and support clinical traceability.

The company’s flagship products fall under the Motiva® brand, which includes a range of ergonomic and round breast implants featuring SilkSurface® texturing and an embedded Q Inside® Safety microtransponder for unique implant identification.